Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of carbon nanoparticles and indocyanine green (ICG) forms a multifunctional nanoplatform primarily used for cancer imaging and therapy. Carbon nanoparticles serve as carriers that enhance the stability, tumor-targeting ability, and photothermal conversion efficiency of ICG—a near-infrared fluorescent dye approved for clinical imaging. This combination is utilized in sentinel lymph node mapping (notably in endometrial and thyroid cancers), intraoperative tumor visualization, dual-modal imaging (fluorescence/magnetic resonance), and photothermal or photodynamic therapy. The formulation improves the photostability of ICG, enables deeper tissue penetration for fluorescence-guided surgery, allows more accurate identification of metastatic nodes or sentinel lymph nodes compared to either agent alone, and can be engineered to deliver additional therapeutic effects such as calcium overload or glutathione depletion in tumors[2][3][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbon nanoparticles + indocyanine green.